Mallinckrodt Rheumatoid Arthritis Phase 4 Clinical Study for H.P. Acthar® Gel (Repository Corticotropin Injection) Achieves its Enrollment Target

Print More
Mallinckrodt logo

STAINES-UPON-THAMES, United Kingdom, June 28, 2018 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today announced it has completed enrollment of the company's ongoing Phase 4

Comments are closed.